samedan logo

home > news > detailed info

Royal Berkshire Hospital innovates with Archer data automation


Reading UK, 03 March 2022:
As an exemplar for developing the ‘Digital Hospital’ and active clinical research organisation, the Royal Berkshire NHS Foundation Trust (RBFT) has given the greenlight to IgniteData’s data automation platform, Archer, for use in clinical trials. This is the first time the Trust has introduced SMART on FHIR technology, specifically backing Archer because it will reduce the need for staff to key in patient research data manually, thereby eliminating errors, saving time and money and increasing capacity for more patient recruitment.

Building on its reputation for digital transformation, RBFT will use the SMART on FHIR application to automatically transfer patient data – such as vital signs, laboratory, medication and past medical history – between the hospital’s Electronic Health Record (EHR) and the Electronic Data Capture (EDC) systems used to run clinical studies.

Archer is a SMART app so it can be easily installed as an add-on to the EHR. It transfers data in a seamless and secure way: as well as speeding up the data capture process, Archer reduces the time hospitals have to spend double-checking the data (SDV) they capture by at least 20%.

Professor Atul Kapila, Director of Research & Development, RBFT commented, “It has been a pleasure to collaborate with the IgniteData team over the last few years, and I am extremely impressed by the potential capabilities that Archer’s EHR to EDC platform will bring to our clinical research teams.

“Royal Berkshire NHS Foundation Trust has gained a reputation as an early adopter of innovative digital technology in patient care through our Digital Hospital Programme. With the introduction of Archer, we are once again embracing digital innovation, positioning ourselves at the leading edge of clinical studies in the UK.”

Dan Hydes, CEO of IgniteData said, “We are delighted to announce that Royal Berkshire NHS Foundation Trust is going live with IgniteData’s Archer data automation technology. RBFT has been a firm supporter of Archer on its journey to becoming the successful industry-backed platform it is today: this truly marks a landmark step in our mission to play our part in enabling vital research trials to get underway as quickly and efficiently as possible using data automation.”
phone +44 118 453 0403
email 400 Thames Valley Park Drive, Reading, RG6 1PT
Print this page
Send to a friend
News and Press Releases

Cerevance Establishes Strategic Research Collaboration with Merck for the Discovery of Novel Targets in Alzheimer’s Disease

Boston, MA and Cambridge, UK – AUGUST 9, 2022: Cerevance, a private, clinical-stage drug discovery and development company focused on central nervous system (CNS) diseases, today announced a multi-year strategic research collaboration with Merck, known as MSD outside the United States and Canada, to identify novel targets for Alzheimer’s disease utilizing Cerevance’s proprietary Nuclear Enriched Transcript Sort sequencing (NETSseq) technology platform. Cerevance will concurrently out-license one discovery-stage program to Merck as part of the collaboration.
More info >>

White Papers

Extractables and Leachables Testing: A Risk Based Approach


Pharmaceutical products are in contact with many external components during both manufacture and usage and small amounts of chemicals may leach from these components with a potential health risk to the patient. Extractables and leachables (E&L) studies therefore play an important role in verifying the safety of a drug product over its lifetime. Regulatory organisations such as the US Food and Drug Administration (FDA) and the European Medicines Agency (EMEA) are taking an increased interest in the interactions of various drug delivery devices, pharmaceutical product containers and medical devices with drug product and/or patient and this field is therefore growing in importance. Regulatory guidelines indicate that an extractables profile should be determined for all materials that contact the drug product. Once established, this profile can be used to determine whether any of these extractables are present as leachables within the product. If a leachable is detected, amounts can be determined using validated analytical methods, after which a biological risk can be established based on the exposure. This white paper will provide an overview of the processes used to determine extractables and leachables from plastics.
More info >>

Industry Events

Connect in Pharma

14-15 September 2022, Plaexpo, Geneva, Switzerland

The new event driving innovation for pharma and biopharma businesses, Connect in Pharma will unite key players in Pharmaceutical and Biopharmaceutical packaging and production in Geneva on 14 – 15 September 2022.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement